

Innovative Bioincubator and Pre-Clinical Contract Research Organization

Offering Extensive Research Discovery Products and Services

Dr. Raphael Nir Co-Founder, President, and CSO

November 2024













NCE's to clinical trials.

approval in July of 2019.

Accomplishments

- SBH Sciences is an innovative Bioincubator and Contract Research Organization (CRO).
- We have been operating for over 27 years, and have been providing over 350 biotechnology companies with high-quality products and services.
- SBH Sciences has supported many start-up companies. We have collaborated with three companies through all stages of drug development, bringing seven
- One of the Seven drugs, Xpovio, was granted FDA

Cell-Based Products

SBH Sciences has produced and commercialized 30 recombinant cytokines, 8 enzymes, and 40 Monoclonal Antibodies. Please contact for custom requests.

Recombinant Cytokines

- Activin-A Bone Morphogenic Proteins (BMP-2, BMP-7) CD22 Growth Factors (HGF)
 - GDF-15/MIC-1*
 - IGF-BPs (IGF-BP-6)
 - Interferon (IFN-b)
 - Interleukins (IL-12, IL-23)**
 - Soluble receptors (s-IL-6R)
 - TGF-Beta (TGF-b2)
 - NF Receptor (HVEM-Fc)


Enzymes

8 Glycosyltransferases


Monoclonal Antibodies

- Anti-TNF-alpha
- Anti-VEGF
- Anti-Gelectin-3
- Anti-T
 - Anti-Tn
- Anti-STn





Extensive Services Offered to Support and Accelerate Your Research Programs



Monoclonal Antibodies Development (in collaboration with Caerus)

Cell Culture

FACS

Formulation

S ta bility



- **Development of Biologics**
- Protein Purification
- Analytical HPLC
- ELISA / RBA (e.g., PD1/2 binding assay)
- Anti-Drug Antibody (ADA) assay

Comprehensive Biomarker Analysis Services



SBH has 11 state-of-the-art biomarker analysis platforms including Luminex, MSD, Ella, Jess, SMCxPRO, FACS, and qRT-PCR.



SBH is the first CRO to offer automated simple western blot services on "Peggy Sue", "Wes", and "Jess" (Protein Simple).



SBH Diagnostics, our strategic partner company, is a Contract Research Organization providing biomarker analysis under CLIA certification and GLP guidelines.



We assist companies and enable translation from non-regulated to regulated environment (clinical trials).



. .

SBH Sciences

Eleven Platforms to assist with Biomarker analysis



BD Accuri C6 **BD** Biosciences

CLAIROstar BMG Labtech

Ella ProteinSimple IsoLight IsoPlexis



Peggy Sue **ProteinSimple**



QuickPlex SQ 120 MSD







StepOne PCR **Applied Biosystems**











Jess ProteinSimple

Luminex 200 Luminex







Bioanalytical Services

Analysis of biological matrix such as blood, serum, plasma, urine and tissue samples



ELISA-Based Assays



Receptor / Ligand - Binding Assay



Anti-Drug Antibodies (ADA)



Immunogenicity neutralizing antibody assays (Nab)



Analytical HPLC




Chromatography



- Pharmacokinetics (PK) and
- Pharmacodynamics (PD)
- Multiplex Services (Luminex, ELLA, MSD, IsoLight)
- Automatic Western Blot (Jess / Wes)
- Endotoxin
- Cell-Based Potency Assays
- Flow-Cytometer Based Assays

Comprehensive Pathway Analysis (Companion Biomarkers)








Stress Response

JAK/STAT

SBH Sciences

Cell Culture Services

Mammalian and Insect Cells





Optimization of growth conditions (media optimization and serum-free adaptation)



Multi-liter supply of any mammalian cell line, before or after cytokines stimulation



Customized services (10 human primary cells and > 500 mammalian cell lines are currently available)



Creation of new stable cell lines



- 2D and 3D assay capabilities including Organoids (in collaboration with Bonds Biosystems)
- Irradiation experiments (combination of anticancer therapy)
- Preparation and isolation of Exosomes
- Commercial production of cell culture spent media (8 years; 19 lots; > 150 L each lot)

Protein Purification Services

For biologics




Development of scalable, well-validated, and reproducible purification processes



Liquid chromatography capabilities (Ion Exchange, HIC, Affinity, Metal, HA, SEC)

HPLC (Preparative and Analytical methods) development)



Cell Lysate




Protein formulation and stability studies





Protein of Interest

Purification



Pure Proteins

Cell-Based Assay Capabilities

SBH Sciences is best positioned to assist you in therapeutic areas such as inflammation, oncology, and fibrosis

350 cell-based assays to measure cytokine activity (cytokine-induced proliferation, cytokineinduced killing, cytokine release assays, and cytokine neutralization)

GPCR activation to determine chemokine activity (e.g., IL-8, GRO, MCP1)

S creening of therapeutic antibodies for specific activity which includes receptor binding assays, ADCC, ADCP, ADC, CDC assay, and immunocytokines

370 different human cancer cell lines to facilitate in-vitro lead drug optimization (cytotoxicity, invasion, migration and adhesion assays)

Cell-based disease models for compound selection (inflammation/fibrosis – THP-1, RAW 264.7, BEAS-2B, SW-982, human Lung Fibroblast, PBMC, and immortalized liver cell line)



Cell-Based Assay Capabilities (Continued)

- T-Cell Activation (e.g., T-cell-engaging IgG-like antibody targeting FLT3 on AML cells and Activation of the 4-1BB/CD137 pathway on Tcells)
- Co-Culture Experiments [e.g., RAW264.7 and ID8 cancer cells]

Testing for the presence of anti-Adeno-Associated Virus (AAV) in pig serum



agonists]







- Immunostimulation [e.g., transfection of h-PBMC with c-di-AMP (CDN) that activates h-STING and results in the secretion of IFN-alpha that enhances anti-cancer activity]
- TLRs activity [e.g., cytokine induction by TLR

Microglial Activation


Exosome uptake by human macrophages






Cancer Cell Cytotoxicity

370 human cancer cell lines are ready for immediate studies



Irradiation Capability **U87MG cell line**




Low-dose radiation can cause cell morphology changes in U87MG as a post-radiation model system.





T-Cell Activation

Human IL-2 secreted by Jurkat clone EG-1 cells after stimulation with immobilized anti-CD3 and soluble anti-CD28







Cells Only

Drug Development Solutions Examples of discovery projects supported by SBH Sciences in the last 3 years

Inflammation: Ι.

Differentiation of THP-1 cells to:

- M1 (IFN-gamma & LPS)
- M2 (IL-13 & IL-4)
- WES Analysis of iNOS expression by RAW 264.7 cells.
- Measurement of TLR-4, TLR-5, TLR-7, TLR-8 & TLR-9 agonist activity using

the SEAP reporter HEK293 or THP1 cell lines.

Screening Agonist / Antagonist compounds targeting CB1 & CB2 receptors.

- Experiments using isolated: Neutrophil, Eosinophils, Basophils Π.
- Modulation of T-cell activation. III.
- IV. Isolation of Stem Cells from Human Milk.
- V. Pig, Rat and Mouse Scale up of intestinal organoids (ileum & duodenum) and transfect and create stable cells prior to in-vivo transplantation.



Drug Development Solutions

Examples of discovery projects supported by SBH Sciences (continued)

- VI. Optimization of adeno-associated virus (AAV) vector design and function in cell lines, primary cells, and ex-vivo tissues and organoids.
- VII. Transfection of mouse and human pancreatic beta-cell lines. Transduction of pancreatic beta cell lines and mouse and human islets.
- VIII. qPCR assays for vector copy number and AAV titer.
- IX. Investigate the potential of IL2/IL12 fusion protein to induce potent anti-tumor immunity.
- X. Isolation of NK cells from human PBMC and investigate the role of NKG2D receptor MICA interaction by FACS analysis.
- XI. Screening RNA-targeting therapeutics compounds as an innovative anti-cancer drug.XII. Development of cell-based assay to assess the activity of virus-like particles containing CpG-A
- XII. Development of cell-based assay to assess the activity of DNA to stimulate TLR9 activity.
- XIII. Screening of hundreds of peptides against multi-targets (e


Solutions BH Sciences (continued)

ce potent anti-tumor immunity. he role of NKG2D receptor –



Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)


Promega Kit (G7010; 12.8-Fold Effector-to-Target) Using SK-BR-3 Cells







Human IL-6 secretion by THP-1 cells stimulated with LPS alone or in combination with IFN-gamma after Complete Media Change (CMC) to remove PMA or No Media Change




Treatment and Concentration



In-Vitro Inflammation Model 1


Differentiated THP1, Positive Control: Clobetasol Stimulation by: 1.25 ng/ml LPS + 0.5 ng/ml IFN-gamma





In-Vitro Inflammation Model 2

Treatment of human PBMC by 10 ug/ml R-848 **Assay Positive Control: Dexamethasone** 24 Hrs. of Exposure




Dexamethasone (uM) [Log Scale]

SCIENCES




h-IL-1b Secretion by THP-1 Cells Treated with Compound C in Combination with 10ng/ml IFN-gamma and 2.5ng/ml LPS for 3 Days (M1) (Pre-Treatment with PMA for 3 days prior to the experiment)



Please note: Up to 100 uM Compound C did not cause any cytotoxicity effect on the cells.




Polarization / Differentiation of THP1 Cells (M2)








RAW 264.7 Cells iNOS Peak Area with WES Analysis (ProteinSimple)






HEK-TLR7 Cells Bioassay of Resiquimod (R-848) Treatment for 46 Hours Alkaline Phosphatase Activity










In-Vitro Fibrosis Model


h-Pro-Collagen I Production by human Lung Fibroblast Cells Treated with 3 and 10 ng/ml TGF-b1 for 48 or 72 Hours (Diluted 1:250 or 1:500 Fold prior to ELISA)








Untreated GBM



The radial spread in two dimensions is reminiscent of the natural disease. Not shown here is the invasion down into the substrate as well.





Clinical Product Development

Case Study: Human IL-12, a Novel Radiation Medical Countermeasure

Proprietary human IL-12 production process was developed by SBH Sciences

COA was established for commercial release to the R&D market

Neumedicines, Inc. (CA) licensed the technology from SBH Sciences



in 2009, SBH Sciences optimized the process, scale-up, and transferred the technology to a GMP manufacturing

2011- Submission of IND and First-In-Human for Toxicity studies










Partnerships

- Galectin Therapeutics and SBH Sciences, announce the formation of
 - Galectin Sciences, LLC,
- Collaborative Venture for Research and Development Galectin Inhibitors for Oral Administration
 - 5 Provisional Patents have been submitted 2 Issued Patent












Improved specificity of Galectin-3 modulators


In a receptor-based EUSA (A), TD139 inhibits binding of multiple galectins to integrin α**M**β**2 (B)**.

An allosteric Gal-3 inhibitor (G229) shows significantly greater specificity for Gal-3 over other galectins (C).






Key Roles at SBH







Company Structure







Create Your Competitive Advantage

Seamlessly Transition Your Product from Early Development to Preclinical and Clinical Stages



SBH Sciences

Let us help you.

Email: rnir@sbhsciences.com

Website: sbhsciences.com

Phone Number: (508)-650-6218

Main Location: 4 Strathmore Rd Natick, MA

Secondary Location: 27 Strathmore Rd Natick, MA



